Comment on Schumacher et al. Shared Decision-Making Feasibility Gap in Obesity and Type 2 Diabetes Care

In their article in Diabetes Care, Schumacher et al. (1) highlight a pressing reality: despite the high coexistence of obesity and type 2 diabetes, the structures needed to support shared decision-making (SDM) remain misaligned with the complexity of contemporary obesity care. Their synthesis is timely, yet the gap between the aspiration of SDM and its feasibility in routine practice continues to widen.

A foundational issue emerges early. SDM is framed as a communication step that follows the presentation of treatment options. In practice, SDM begins far earlier—at the level of disease perception. Many individuals with obesity accept the medical framing of obesity as a chronic disease while feeling personally responsible for its management, a tension reinforced by longstanding clinical and societal narratives (2). This cognitive dissonance shapes expectations, openness to treatment, and willingness to participate in SDM. Unless these dynamics are addressed explicitly, SDM risks becoming a procedural ritual rather than a meaningful clinical partnership.

The review would benefit from a unifying, staging-informed implementation framework integrating clinical severity, provider competencies, and system-level feasibility. Without such a framework, the multiple barriers described—knowledge gaps, sociocultural influences, fragmented referral pathways, limited access to treatments, and rapid therapeutic innovation—remain parallel obstacles rather than components of a coherent decision-making ecology. This mismatch constitutes what we define as the SDM feasibility gap, the distance between therapeutic complexity and the system’s capacity to support informed, proportionate choice. Contemporary clinical guidelines emphasize staging-based assessment and treatment alignment, underscoring the need for structured, severity-informed decision pathways (3).

A clinical scenario illustrates this gap. In practice, the coexistence of obesity and type 2 diabetes often amplifies the tension between patient expectations and clinical priorities. A patient influenced by social media messaging may request a specific glucagon-like peptide-1 agent despite advanced disease severity suggesting the need for more intensive interventions or metabolic surgery. The clinician must reconcile staging, eligibility, coverage constraints, and expectations while managing glycemic control and competing priorities. Without structural supports, SDM in such encounters becomes not merely difficult but illusory.

The review notes the promise of decision aids, electronic decision support, structured counseling models, artificial intelligence, and patient navigators, yet these innovations require workflow integration, clarity of provider roles, and alignment with health system structures. A scalable SDM model for obesity and type 2 diabetes should rest on three pillars: staging-informed treatment alignment, structured decision aids embedded in workflows, and system-level feasibility ensuring realistic access to evidence-based options. Contemporary SDM frameworks provide a conceptual foundation for this integration but require adaptation to the complexity of obesity care (4). This need is even more pronounced in health systems outside the U.S., where access pathways and reimbursement structures differ substantially.

In summary, Schumacher et al. underscore the importance of SDM, but its potential will not be realized until the field moves beyond cataloging barriers and begins constructing a coherent, scalable, staging-informed framework. Only by aligning clinical complexity with system capacity can SDM evolve from an aspirational ideal to a reliable component of everyday practice—closing, at last, the SDM feasibility gap.